Enhancing the Pharmacokinetic/Pharmacodynamic Properties of Therapeutic Nucleotides Using Lipid Nanoparticle Systems

References

• Allen TM , CullisPR. Drug delivery systems: entering the mainstream. Science303, 1818–1822 (2004).
   PubMed Web of Science ®Google Scholar
• Lin PJ , TamYY, HafezIet al. Influence of cationic lipid composition on uptake and intracellular processing of lipid nanoparticle formulations of siRNA. Nanomedicine9 (2), 233–246 (2013).
   PubMed Web of Science ®Google Scholar
• Gilleron J , QuerbesW, ZeigererAet al. Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape. Nat. Biotechnol.31 (7), 638–646 (2013).
   PubMed Web of Science ®Google Scholar
• Dias N , SteinCA. Antisense oligonucleotides: basic concepts and mechanisms. Mol. Cancer Ther.1 (5), 347–355 (2002).
   PubMed Web of Science ®Google Scholar
• Barros SA , GollobJA. Safety profile of RNAi nanomedicines. Adv. Drug Del. Rev.64 (15), 1730–1737 (2012).
   PubMed Web of Science ®Google Scholar
• Kashani-Sabet M . Ribozyme therapeutics. J. Invest. Dermatol.7 (1), 76–78 (2002).
   Web of Science ®Google Scholar
• Chan CW , KhachigianLM. Dnazymes and their therapeutic possibilities. Intern. Med. J.39 (4), 249–251 (2009).
   PubMed Web of Science ®Google Scholar
• Behlke MA . Chemical modification of siRNAs for in vivo use. Oligonucleotides18 (4), 305–319 (2008).
   PubMed Web of Science ®Google Scholar
• Leung AK , TamYY, ChenS, HafezIM, CullisPR. Microfluidic mixing: a general method for encapsulating macromolecules in lipid nanoparticle systems. J. Phys. Chem. B119 (28), 8698–8706 (2015).
   PubMed Web of Science ®Google Scholar
• Belliveau NM , HuftJ, LinPJet al. Microfluidic synthesis of highly potent limit-size lipid nanoparticles for in vivo delivery of siRNA. Mol. Ther. Nucleic Acids1, e37 (2012).
   PubMedGoogle Scholar
• Leung AK , HafezIM, BaoukinaSet al. Lipid nanoparticles containing siRNA synthesized by microfluidic mixing exhibit an electron-dense nanostructured core. J. Phys. Chem. C Nanomater Interfaces116 (34), 18440–18450 (2012).
   PubMed Web of Science ®Google Scholar
• Nicolau C , Le PapeA, SorianoP, FargetteF, JuhelMF. In vivo expression of rat insulin after intravenous administration of the liposome-entrapped gene for rat insulin i. Proc. Natl. Acad. Sci. USA80 (4), 1068–1072 (1983).
   PubMed Web of Science ®Google Scholar
• Gao X , HuangL. A novel cationic liposome reagent for efficient transfection of mammalian cells. Biochem. Biophys. Res. Commun.179 (1), 280–285 (1991).
   PubMed Web of Science ®Google Scholar
• Oussoren C , StormG. Lymphatic uptake and biodistribution of liposomes after subcutaneous injection: Iii. Influence of surface modification with poly(ethyleneglycol). Pharm. Res.14 (10), 1479–1484 (1997).
   PubMed Web of Science ®Google Scholar
• Semple SC , AkincA, ChenJet al. Rational design of cationic lipids for siRNA delivery. Nat. Biotechnol.28 (2), 172–176 (2010).
   PubMed Web of Science ®Google Scholar
• Zimmermann TS , LeeAC, AkincAet al. RNAi-mediated gene silencing in non-human primates. Nature441 (7089), 111–114 (2006).
   PubMed Web of Science ®Google Scholar
• Maurer N , WongKF, StarkHet al. Spontaneous entrapment of polynucleotides upon electrostatic interaction with ethanol-destabilized cationic liposomes. Biophys. J.80 (5), 2310–2326 (2001).
   PubMed Web of Science ®Google Scholar
• Jeffs LB , PalmerLR, AmbegiaEG, GiesbrechtC, EwanickS, MaclachlanI. A scalable, extrusion-free method for efficient liposomal encapsulation of plasmid DNA. Pharm. Res.22 (3), 362–372 (2005).
   PubMed Web of Science ®Google Scholar
• Raney SG , WilsonKD, SekirovLet al. The effect of circulation lifetime and drug-to-lipid ratio of intravenously administered lipid nanoparticles on the biodistribution and immunostimulatory activity of encapsulated Cpg-Odn. J. Drug Target.16 (7), 564–577 (2008).
   PubMed Web of Science ®Google Scholar
• Chono S , LiSD, ConwellCC, HuangL. An efficient and low immunostimulatory nanoparticle formulation for systemic siRNA delivery to the tumor. J. Control. Release131 (1), 64–69 (2008).
   PubMed Web of Science ®Google Scholar
• Rungta RL , ChoiHB, LinPJet al. Lipid nanoparticle delivery of siRNA to silence neuronal gene expression in the brain. Mol. Ther. Nucleic Acids2, e136 (2013).
   PubMedGoogle Scholar
• Senn C , HangartnerC, MoesS, GueriniD, HofbauerKG. Central administration of small interfering RNAs in rats: a comparison with antisense oligonucleotides. Eur. J. Pharmacol.522 (1–3), 30–37 (2005).
   PubMed Web of Science ®Google Scholar
• Rungta RL , ChoiHB, TysonJRet al. The cellular mechanisms of neuronal swelling underlying cytotoxic edema. Cell161 (3), 610–621 (2015).
   PubMed Web of Science ®Google Scholar
• Felgner PL , GadekTR, HolmMet al. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc. Natl Acad. Sci. USA84 (21), 7413–7417 (1987).
   PubMed Web of Science ®Google Scholar
• Felgner PL , RingoldGM. Cationic liposome-mediated transfection. Nature337 (6205), 387–388 (1989).
   PubMed Web of Science ®Google Scholar
• Wolfrum C , ShiS, JayaprakashKNet al. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat. Biotechnol.25 (10), 1149–1157 (2007).
   PubMed Web of Science ®Google Scholar
• Querbes W , GeP, ZhangWet al. Direct CNS delivery of siRNA mediates robust silencing in oligodendrocytes. Oligonucleotides19 (1), 23–29 (2009).
   PubMedGoogle Scholar
• Chen Q , ButlerD, QuerbesWet al. Lipophilic siRNAs mediate efficient gene silencing in oligodendrocytes with direct CNS delivery. J. Control. Release144 (2), 227–232 (2010).
   PubMed Web of Science ®Google Scholar
• Yamada T , PengCG, MatsudaSet al. Versatile site-specific conjugation of small molecules to siRNA using click chemistry. J. Org. Chem.76 (5), 1198–1211 (2011).
   PubMed Web of Science ®Google Scholar
• Soutschek J , AkincA, BramlageBet al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature432 (7014), 173–178 (2004).
   PubMed Web of Science ®Google Scholar
• Lorenz C , HadwigerP, JohnM, VornlocherHP, UnverzagtC. Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells. Bioorg. Med. Chem. Lett.14 (19), 4975–4977 (2004).
   PubMed Web of Science ®Google Scholar
• Nakayama T , ButlerJS, SehgalAet al. Harnessing a physiologic mechanism for siRNA delivery with mimetic lipoprotein particles. Mol. Ther.20 (8), 1582–1589 (2012).
   PubMed Web of Science ®Google Scholar
• Sebestyen MG , WongSC, TrubetskoyV, LewisDL, WooddellCI. Targeted in vivo delivery of siRNA and an endosome-releasing agent to hepatocytes. Methods Mol. Biol.1218, 163–186 (2015).
   PubMedGoogle Scholar
• Wooddell CI , RozemaDB, HossbachMet al. Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis b virus infection. Mol. Ther.21 (5), 973–985 (2013).
   PubMed Web of Science ®Google Scholar
• Wong SC , KleinJJ, HamiltonHLet al. Co-injection of a targeted, reversibly masked endosomolytic polymer dramatically improves the efficacy of cholesterol-conjugated small interfering RNAs in vivo. Nucleic Acid Ther.22 (6), 380–390 (2012).
   PubMed Web of Science ®Google Scholar
• Matsuda S , KeiserK, NairJKet al. siRNA conjugates carrying sequentially assembled trivalent N-acetylgalactosamine linked through nucleosides elicit robust gene silencing in vivo in hepatocytes. ACS Chem. Biol.10 (5), 1181–1187 (2015).
   PubMed Web of Science ®Google Scholar
• Nair JK , WilloughbyJL, ChanAet al. Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J. Am. Chem. Soc.136 (49), 16958–16961 (2014).
   PubMed Web of Science ®Google Scholar
• Rajeev KG , NairJK, JayaramanMet al. Hepatocyte-specific delivery of siRNAs conjugated to novel non-nucleosidic trivalent n-acetylgalactosamine elicits robust gene silencing in vivo. Chembiochem16 (6), 903–908 (2015).
   PubMed Web of Science ®Google Scholar
• Alnylam Pharmaceuticals . TIDES 2014: GaINAc-siRNA with enhanced stabilization chemistry: ESC-GaINAc-siRNA. www.alnylam.com/web/assets/ALNY-ESC-GalNAc-siRNA-TIDES-May2014-Capella.pdf.
   Google Scholar
• Lim LP , LauNC, Garrett-EngelePet al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature433 (7027), 769–773 (2005).
   PubMed Web of Science ®Google Scholar
• Gu S , KayMA. How do miRNAs mediate translational repression?Silence1 (1), 11 (2010).
   PubMedGoogle Scholar
• Bartel DP . MicroRNAs: target recognition and regulatory functions. Cell136 (2), 215–233 (2009).
   PubMed Web of Science ®Google Scholar
• Wang WT , ChenYQ. Circulating miRNAs in cancer: from detection to therapy. J. Hematol. Oncol.7 (1), 86 (2014).
   PubMedGoogle Scholar
• Femminella GD , FerraraN, RengoG. The emerging role of microRNAs in Alzheimer's disease. Front. Physiol.6, 40 (2015).
   PubMed Web of Science ®Google Scholar
• Katoh M . Cardio-miRNAs and onco-miRNAs: circulating miRNA-based diagnostics for non-cancerous and cancerous diseases. Front. Cell Dev. Biol.2, 61 (2014).
   PubMed Web of Science ®Google Scholar
• Castro-Villegas C , Perez-SanchezC, EscuderoAet al. Circulating miRNAs as potential biomarkers of therapy effectiveness in rheumatoid arthritis patients treated with anti-tnfalpha. Arthritis Res. Ther.17 (1), 49 (2015).
   PubMedGoogle Scholar
• Mi S , ZhangJ, ZhangW, HuangRS. Circulating microRNAs as biomarkers for inflammatory diseases. MicroRNA2 (1), 63–71 (2013).
   PubMedGoogle Scholar
• Krutzfeldt J , RajewskyN, BraichRet al. Silencing of microRNAs in vivo with ‘antagomirs’. Nature438 (7068), 685–689 (2005).
   PubMed Web of Science ®Google Scholar
• Zhang Y , WangZ, GemeinhartRA. Progress in microRNA delivery. J. Control. Release172 (3), 962–974 (2013).
   PubMed Web of Science ®Google Scholar
• Braasch DA , ParooZ, ConstantinescuAet al. Biodistribution of phosphodiester and phosphorothioate siRNA. Bioorg. Med. Chem. Lett.14 (5), 1139–1143 (2004).
   PubMed Web of Science ®Google Scholar
• Gao S , Dagnaes-HansenF, NielsenEJet al. The effect of chemical modification and nanoparticle formulation on stability and biodistribution of siRNA in mice. Mol. Ther.17 (7), 1225–1233 (2009).
   PubMed Web of Science ®Google Scholar
• Thompson JD , KornbrustDJ, FoyJWet al. Toxicological and pharmacokinetic properties of chemically modified siRNAs targeting p53 RNA following intravenous administration. Nucleic Acid Ther.22 (4), 255–264 (2012).
   PubMed Web of Science ®Google Scholar
• Devincenzo J , CehelskyJE, AlvarezRet al. Evaluation of the safety, tolerability and pharmacokinetics of aln-rsv01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). Antiviral Res.77 (3), 225–231 (2008).
   PubMed Web of Science ®Google Scholar
• Alnylam Pharmaceuticals . Results of a Phase 2b multi-center, randomized, double-blind, placebo-controlled study of an RNAi therapeutic, ALN-RSV01, in respiratory syncytial virus (RSV)-infected lung transplant patients. www.alnylam.com/web/wp-content/uploads/2012/09/RSV01-109-ERS-Oral-Final-24Aug2012.pdf.
   Google Scholar
• Esau C , DavisS, MurraySFet al. Mir-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab.3 (2), 87–98 (2006).
   PubMed Web of Science ®Google Scholar
• Lanford RE , Hildebrandt-EriksenES, PetriAet al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis c virus infection. Science327 (5962), 198–201 (2010).
   PubMed Web of Science ®Google Scholar
• Elmen J , LindowM, SchutzSet al. LNA-mediated microRNA silencing in non-human primates. Nature452 (7189), 896–899 (2008).
   PubMed Web of Science ®Google Scholar
• Hofland HE , ShephardL, SullivanSM. Formation of stable cationic lipid/DNA complexes for gene transfer. Proc. Natl Acad. Sci. USA93 (14), 7305–7309 (1996).
   PubMed Web of Science ®Google Scholar
• Stewart MJ , PlautzGE, Del BuonoLet al. Gene transfer in vivo with DNA-liposome complexes: safety and acute toxicity in mice. Hum. Gene Ther.3 (3), 267–275 (1992).
   PubMed Web of Science ®Google Scholar
• San H , YangZY, PompiliVJet al. Safety and short-term toxicity of a novel cationic lipid formulation for human gene therapy. Hum. Gene Ther.4 (6), 781–788 (1993).
   PubMed Web of Science ®Google Scholar
• Hafez IM , CullisPR. Roles of lipid polymorphism in intracellular delivery. Adv. Drug Deliv. Rev.47 (2–3), 139–148 (2001).
   PubMed Web of Science ®Google Scholar
• Semple SC , KlimukSK, HarasymTOet al. Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures. Biochim. Biophys. Acta1510 (1–2), 152–166 (2001).
   PubMed Web of Science ®Google Scholar
• Cullis PR , ChonnA, SempleSC. Interactions of liposomes and lipid-based carrier systems with blood proteins: relation to clearance behaviour in vivo. Adv. Drug Deliv. Rev.32 (1–2), 3–17 (1998).
   PubMed Web of Science ®Google Scholar
• Jayaraman M , AnsellSM, MuiBLet al. Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. Angew. Chem. Int. Ed. Engl.51 (34), 8529–8533 (2012).
   PubMed Web of Science ®Google Scholar
• Coelho T , AdamsD, SilvaAet al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N. Engl. J. Med.369 (9), 819–829 (2013).
   PubMed Web of Science ®Google Scholar
• Akinc A , QuerbesW, DeSet al. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol. Ther.18 (7), 1357–1364 (2010).
   PubMed Web of Science ®Google Scholar
• Maier MA , JayaramanM, MatsudaSet al. Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics. Mol. Ther.21 (8), 1570–1578 (2013).
   PubMed Web of Science ®Google Scholar
• Dong Y , LoveKT, DorkinJRet al. Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates. Proc. Natl Acad. Sci. USA111 (11), 3955–3960 (2014).
   PubMed Web of Science ®Google Scholar
• Huang L , SullengerB, JulianoR. The role of carrier size in the pharmacodynamics of antisense and siRNA oligonucleotides. J. Drug Target.18 (8), 567–574 (2010).
   PubMed Web of Science ®Google Scholar
• Moreno PM , PegoAP. Therapeutic antisense oligonucleotides against cancer: hurdling to the clinic. Front. Chem.2, 87 (2014).
   PubMed Web of Science ®Google Scholar
• Mui BL , TamYK, JayaramanMet al. Influence of polyethylene glycol lipid desorption rates on pharmacokinetics and pharmacodynamics of siRNA lipid nanoparticles. Mol. Ther. Nucleic Acids2, e139 (2013).
   PubMedGoogle Scholar
• Wilson SC , BaryzaJL, ReynoldsAJet al. Real time measurement of peg shedding from lipid nanoparticles in serum via nmr spectroscopy. Mol. Pharm.12 (2), 386–392 (2015).
   PubMedGoogle Scholar
• Liu Y , HuY, HuangL. Influence of polyethylene glycol density and surface lipid on pharmacokinetics and biodistribution of lipid-calcium-phosphate nanoparticles. Biomaterials35 (9), 3027–3034 (2014).
   PubMed Web of Science ®Google Scholar
• Yamamoto Y , LinPJ, BeraldiEet al. siRNA lipid nanoparticle potently silence clusterin and delay progression when combined with androgen receptor co-targeting in enzalutamide resistant prostate cancer. Clin. Cancer Res. doi:10.1158/1078-0432.CCR-15-0866 (2015) ( Epub ahead of print).
   Web of Science ®Google Scholar
• Chen S , TamYY, LinPJ, LeungAK, TamYK, CullisPR. Development of lipid nanoparticle formulations of siRNA for hepatocyte gene silencing following subcutaneous administration. J. Control. Release196, 106–112 (2014).
   PubMed Web of Science ®Google Scholar
• Takeuchi H , KojimaH, YamamotoH, KawashimaY. Evaluation of circulation profiles of liposomes coated with hydrophilic polymers having different molecular weights in rats. J. Control. Release75 (1–2), 83–91 (2001).
   PubMed Web of Science ®Google Scholar
• Takeuchi H , KojimaH, YamamotoH, KawashimaY. Polymer coating of liposomes with a modified polyvinyl alcohol and their systemic circulation and res uptake in rats. J. Control. Release68 (2), 195–205 (2000).
   PubMed Web of Science ®Google Scholar
• Nag OK , YadavVR, CroftB, HedrickA, AwasthiV. Liposomes modified with superhydrophilic polymer linked to a nonphospholipid anchor exhibit reduced complement activation and enhanced circulation. J. Pharm. Sci.104 (1), 114–123 (2015).
   PubMed Web of Science ®Google Scholar
• Loyer P , Cammas-MarionS. Natural and synthetic poly(malic acid)-based derivates: a family of versatile biopolymers for the design of drug nanocarriers. J. Drug Target.22 (7), 556–575 (2014).
   PubMed Web of Science ®Google Scholar
• Kim JC , ChungtYI, KimYH, TaeG. The modulation of the permeability and the cellular uptake of liposome by stable anchoring of lipid-conjugated pluronic on liposome. J. Biomed. Nanotechnol.10 (1), 100–108 (2014).
   PubMed Web of Science ®Google Scholar
• Zhou Y , NingQ, YuDN, LiWG, DengJ. Improved oral bioavailability of breviscapine via a pluronic p85-modified liposomal delivery system. J. Pharm. Pharmacol.66 (7), 903–911 (2014).
   PubMed Web of Science ®Google Scholar
• Abu Lila AS , NawataK, ShimizuT, IshidaT, KiwadaH. Use of polyglycerol (PG), instead of polyethylene glycol (PEG), prevents induction of the accelerated blood clearance phenomenon against long-circulating liposomes upon repeated administration. Int. J. Pharm.456 (1), 235–242 (2013).
   PubMed Web of Science ®Google Scholar
• Lu T , WangZ, MaY, ZhangY, ChenT. Influence of polymer size, liposomal composition, surface charge, and temperature on the permeability of pH-sensitive liposomes containing lipid-anchored poly(2-ethylacrylic acid). Int. J. Nanomed.7, 4917–4926 (2012).
   PubMed Web of Science ®Google Scholar
• Araki T , KonoY, OgawaraKet al. Formulation and evaluation of paclitaxel-loaded polymeric nanoparticles composed of polyethylene glycol and polylactic acid block copolymer. Biol. Pharm. Bull.35 (8), 1306–1313 (2012).
   PubMed Web of Science ®Google Scholar
• Zalipsky S , HansenCB, OaksJM, AllenTM. Evaluation of blood clearance rates and biodistribution of poly(2-oxazoline)-grafted liposomes. J. Pharm. Sci.85 (2), 133–137 (1996).
   PubMed Web of Science ®Google Scholar
• Xu H , ZhangW, LiYet al. The bifunctional liposomes constructed by poly(2-ethyl-oxazoline)-cholesteryl methyl carbonate: an effectual approach to enhance liposomal circulation time, ph-sensitivity and endosomal escape. Pharm. Res.31 (11), 3038–3050 (2014).
   PubMed Web of Science ®Google Scholar
• Woodle MC , EngbersCM, ZalipskyS. New amphipatic polymer-lipid conjugates forming long-circulating reticuloendothelial system-evading liposomes. Bioconjug. Chem.5 (6), 493–496 (1994).
   PubMed Web of Science ®Google Scholar
• Torchilin VP , TrubetskoyVS, WhitemanKR, CalicetiP, FerrutiP, VeroneseFM. New synthetic amphiphilic polymers for steric protection of liposomes in vivo. J. Pharm. Sci.84 (9), 1049–1053 (1995).
   PubMed Web of Science ®Google Scholar
• Whiteman KR , SubrV, UlbrichK, TorchilinVP. Poly(hpma)-coated liposomes demonstrate prolonged circulation in mice. J. Liposome Res.11 (2–3), 153–164 (2001).
   PubMed Web of Science ®Google Scholar
• Yamazaki A , WinnikFM, CorneliusRM, BrashJL. Modification of liposomes with N-substituted polyacrylamides: identification of proteins adsorbed from plasma. Biochim. Biophys. Acta1421 (1), 103–115 (1999).
   PubMed Web of Science ®Google Scholar
• Li SD , HuangL. Stealth nanoparticles: high density but sheddable PEG is a key for tumor targeting. J. Control. Release145 (3), 178–181 (2010).
   PubMed Web of Science ®Google Scholar
• Romberg B , HenninkWE, StormG. Sheddable coatings for long-circulating nanoparticles. Pharm. Res.25 (1), 55–71 (2008).
   PubMed Web of Science ®Google Scholar
• Kumar V , QinJ, JiangYet al. Shielding of lipid nanoparticles for siRNA delivery: impact on physicochemical properties, cytokine induction, and efficacy. Mol. Ther. Nucleic Acids3, e210 (2014).
   PubMedGoogle Scholar
• Tam YY , ChenS, ZaifmanJet al. Small molecule ligands for enhanced intracellular delivery of lipid nanoparticle formulations of siRNA. Nanomedicine9 (5), 665–674 (2013).
   PubMed Web of Science ®Google Scholar
• Qhattal HS , HyeT, AlaliA, LiuX. Hyaluronan polymer length, grafting density, and surface poly(ethylene glycol) coating influence in vivo circulation and tumor targeting of hyaluronan-grafted liposomes. ACS Nano8 (6), 5423–5440 (2014).
   PubMed Web of Science ®Google Scholar
• Ran R , LiuY, GaoHet al. Enhanced gene delivery efficiency of cationic liposomes coated with pegylated hyaluronic acid for anti P-glycoprotein siRNA: a potential candidate for overcoming multi-drug resistance. Int. J. Pharm.477 (1–2), 590–600 (2014).
   PubMed Web of Science ®Google Scholar
• Chen Y , ZhuX, ZhangX, LiuB, HuangL. Nanoparticles modified with tumor-targeting scfv deliver siRNA and miRNA for cancer therapy. Mol. Ther.18 (9), 1650–1656 (2010).
   PubMed Web of Science ®Google Scholar
• Sahay G , QuerbesW, AlabiCet al. Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling. Nat. Biotechnol.31 (7), 653–658 (2013).
   PubMed Web of Science ®Google Scholar
• Jones RA , CheungCY, BlackFEet al. Poly(2-alkylacrylic acid) polymers deliver molecules to the cytosol by pH-sensitive disruption of endosomal vesicles. Biochem. J.372 (Pt 1), 65–75 (2003).
   PubMedGoogle Scholar
• Shi S , HanL, GongT, ZhangZ, SunX. Systemic delivery of microRNA-34a for cancer stem cell therapy. Angew. Chem. Int. Ed. Engl.52 (14), 3901–3905 (2013).
   PubMed Web of Science ®Google Scholar
• Liu N , ZhouC, ZhaoJ, ChenY. Reversal of paclitaxel resistance in epithelial ovarian carcinoma cells by a MUC1 aptamer-let-7i chimera. Cancer Invest.30 (8), 577–582 (2012).
   PubMed Web of Science ®Google Scholar
• Ando H , AsaiT, KoideHet al. Advanced cancer therapy by integrative antitumor actions via systemic administration of mir-499. J. Control. Release181, 32–39 (2014).
   PubMed Web of Science ®Google Scholar
• Hatakeyama H , MurataM, SatoYet al. The systemic administration of an anti-miRNA oligonucleotide encapsulated ph-sensitive liposome results in reduced level of hepatic microRNA-122 in mice. J. Control. Release173, 43–50 (2014).
   PubMed Web of Science ®Google Scholar
• Costa PM , CardosoAL, CustodiaC, CunhaP, De AlmeidaLP, Pedroso De LimaMC. MiRNA-21 silencing mediated by tumor-targeted nanoparticles combined with sunitinib: a new multimodal gene therapy approach for glioblastoma. J. Control. Release207, 31–39 (2015).
   PubMed Web of Science ®Google Scholar
• Liu J , DangL, LiDet al. A delivery system specifically approaching bone resorption surfaces to facilitate therapeutic modulation of microRNAs in osteoclasts. Biomaterials52, 148–160 (2015).
   PubMed Web of Science ®Google Scholar
• Helene C , ToulmeJJ. Specific regulation of gene expression by antisense, sense and antigene nucleic acids. Biochim. Biophys. Acta1049 (2), 99–125 (1990).
   PubMedGoogle Scholar
• Wu H , LimaWF, ZhangH, FanA, SunH, CrookeST. Determination of the role of the human RNAse h1 in the pharmacology of DNA-like antisense drugs. J. Biol. Chem.279 (17), 17181–17189 (2004).
   PubMed Web of Science ®Google Scholar
• Van Roon-Mom WM , Aartsma-RusA. Overview on applications of antisense-mediated exon skipping. Methods Mol. Biol.867, 79–96 (2012).
   PubMedGoogle Scholar
• Kole R , SazaniP. Antisense effects in the cell nucleus: modification of splicing. Curr. Opin. Mol. Ther.3 (3), 229–234 (2001).
   PubMedGoogle Scholar
• Van Deutekom JC , Van OmmenGJ. Advances in duchenne muscular dystrophy gene therapy. Nat. Rev. Genet.4 (10), 774–783 (2003).
   PubMed Web of Science ®Google Scholar
• Marwick C . First “antisense” drug will treat cmv retinitis. JAMA280 (10), 871 (1998).
   PubMed Web of Science ®Google Scholar
• Santos RD , RaalFJ, CatapanoAL, WitztumJL, Steinhagen-ThiessenE, TsimikasS. Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 Phase III trials. Arterioscler. Thromb. Vasc. Biol.35 (3), 689–699 (2015).
   PubMed Web of Science ®Google Scholar
• Crooke ST , GrahamMJ, ZuckermanJEet al. Pharmacokinetic properties of several novel oligonucleotide analogs in mice. J. Pharmacol. Exp. Ther.277 (2), 923–937 (1996).
   PubMed Web of Science ®Google Scholar
• Phillips JA , CraigSJ, BayleyD, ChristianRA, GearyR, NicklinPL. Pharmacokinetics, metabolism, and elimination of a 20-mer phosphorothioate oligodeoxynucleotide (CGP 69846A) after intravenous and subcutaneous administration. Biochem. Pharmacol.54 (6), 657–668 (1997).
   PubMed Web of Science ®Google Scholar
• Leeds JM , HenrySP, GearyR, BurckinT, LevinAA. Comparison of the pharmacokinetics of subcutaneous and intravenous administration of a phosphorothioate oligodeoxynucleotide in cynomolgus monkeys. Antisense Nucleic Acid Drug Dev.10 (6), 435–441 (2000).
   PubMedGoogle Scholar
• Mendell JR , Rodino-KlapacLR, SahenkZet al. Eteplirsen for the treatment of duchenne muscular dystrophy. Ann. Neurol.74 (5), 637–647 (2013).
   PubMed Web of Science ®Google Scholar
• Yu RZ , ZhangH, GearyRSet al. Pharmacokinetics and pharmacodynamics of an antisense phosphorothioate oligonucleotide targeting FAS mRNA in mice. J. Pharmacol. Exp. Ther.296 (2), 388–395 (2001).
   PubMed Web of Science ®Google Scholar
• Yu RZ , GearyRS, MonteithDKet al. Tissue disposition of 2’-o-(2-methoxy) ethyl modified antisense oligonucleotides in monkeys. J. Pharm. Sci.93 (1), 48–59 (2004).
   PubMed Web of Science ®Google Scholar
• Seth PP , SiwkowskiA, AllersonCRet al. Short antisense oligonucleotides with novel 2’-4’ conformationaly restricted nucleoside analogues show improved potency without increased toxicity in animals. J. Med. Chem.52 (1), 10–13 (2009).
   PubMed Web of Science ®Google Scholar
• Yu RZ , KimTW, HongA, WatanabeTA, GausHJ, GearyRS. Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, isis 301012, targeting human apolipoprotein b-100. Drug Metab. Dispos.35 (3), 460–468 (2007).
   PubMed Web of Science ®Google Scholar
• Yu RZ , LemonidisKM, GrahamMJet al. Cross-species comparison of in vivo pk/pd relationships for second-generation antisense oligonucleotides targeting apolipoprotein b-100. Biochem. Pharmacol.77 (5), 910–919 (2009).
   PubMed Web of Science ®Google Scholar
• Bochot A , CouvreurP, FattalE. Intravitreal administration of antisense oligonucleotides: potential of liposomal delivery. Prog. Retin. Eye Res.19 (2), 131–147 (2000).
   PubMed Web of Science ®Google Scholar
• Lysik MA , Wu-PongS. Innovations in oligonucleotide drug delivery. J. Pharm. Sci.92 (8), 1559–1573 (2003).
   PubMed Web of Science ®Google Scholar
• Waterhouse DN , DragowskaWH, GelmonKA, MayerLD, BallyMB. Pharmacodynamic behavior of liposomal antisense oligonucleotides targeting Her-2/neu and vascular endothelial growth factor in an ascitic MDA435/LCC6 human breast cancer model. Cancer Biol. Ther.3 (2), 197–204 (2004).
   PubMed Web of Science ®Google Scholar
• Pakunlu RI , WangY, SaadM, KhandareJJ, StarovoytovV, MinkoT. In vitro and in vivo intracellular liposomal delivery of antisense oligonucleotides and anticancer drug. J. Control. Release114 (2), 153–162 (2006).
   PubMed Web of Science ®Google Scholar
• Garbuzenko OB , SaadM, BetigeriSet al. Intratracheal versus intravenous liposomal delivery of siRNA, antisense oligonucleotides and anticancer drug. Pharm. Res.26 (2), 382–394 (2009).
   PubMed Web of Science ®Google Scholar
• Lo YL , LiuY, TsaiJC. Overcoming multidrug resistance using liposomal epirubicin and antisense oligonucleotides targeting pump and nonpump resistances in vitro and in vivo. Biomed. Pharmacother.67 (4), 261–267 (2013).
   PubMed Web of Science ®Google Scholar
• Andreakos E , RauchhausU, StavropoulosAet al. Amphoteric liposomes enable systemic antigen-presenting cell-directed delivery of cd40 antisense and are therapeutically effective in experimental arthritis. Arthritis Rheum.60 (4), 994–1005 (2009).
   PubMed Web of Science ®Google Scholar
• Arranz A , ReinschC, PapadakisKAet al. Treatment of experimental murine colitis with cd40 antisense oligonucleotides delivered in amphoteric liposomes. J. Control. Release165 (3), 163–172 (2013).
   PubMed Web of Science ®Google Scholar
• Negishi Y , IshiiY, ShionoHet al. Bubble liposomes and ultrasound exposure improve localized morpholino oligomer delivery into the skeletal muscles of dystrophic mdx mice. Mol. Pharm.11 (3), 1053–1061 (2014).
   PubMedGoogle Scholar
• Desjardins JP , SproatBS, BeijerBet al. Pharmacokinetics of a synthetic, chemically modified hammerhead ribozyme against the rat cytochrome P-450 3A2 mRNA after single intravenous injections. J. Pharmacol. Exp. Ther.278 (3), 1419–1427 (1996).
   PubMed Web of Science ®Google Scholar
• Lee PA , BlattLM, BlanchardKSet al. Pharmacokinetics and tissue distribution of a ribozyme directed against hepatitis C virus RNA following subcutaneous or intravenous administration in mice. Hepatology32 (3), 640–646 (2000).
   PubMed Web of Science ®Google Scholar
• Weng DE , MasciPA, RadkaSFet al. A Phase I clinical trial of a ribozyme-based angiogenesis inhibitor targeting vascular endothelial growth factor receptor-1 for patients with refractory solid tumors. Mol. Cancer Ther.4 (6), 948–955 (2005).
   PubMed Web of Science ®Google Scholar
• Morrow PK , MurthyRK, EnsorJDet al. An open-label, Phase 2 trial of RPI.4610 (Angiozyme) in the treatment of metastatic breast cancer. Cancer118 (17), 4098–4104 (2012).
   PubMed Web of Science ®Google Scholar
• Pavco PA , BouhanaKS, GallegosAMet al. Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors. Clin. Cancer Res.6 (5), 2094–2103 (2000).
   PubMed Web of Science ®Google Scholar
• Hallett MA , TengB, HasegawaH, SchwabLP, SeagrovesTN, PourmotabbedT. Anti-matrix metalloproteinase-9 dnazyme decreases tumor growth in the mmtv-pymt mouse model of breast cancer. Breast Cancer Res.15 (1), R12 (2013).
   PubMed Web of Science ®Google Scholar
• Zhou J , YangXQ, XieYYet al. Inhibition of respiratory syncytial virus of subgroups A and B using deoxyribozyme dz1133 in mice. Virus Res.130 (1–2), 241–248 (2007).
   PubMed Web of Science ®Google Scholar
• Balow JE Jr , SheltonDA, OrsbornAet al. A high-resolution genetic map of the familial mediterranean fever candidate region allows identification of haplotype-sharing among ethnic groups. Genomics44 (3), 280–291 (1997).
   PubMed Web of Science ®Google Scholar
• Appaiahgari MB , VratiS. Dnazyme-mediated inhibition of japanese encephalitis virus replication in mouse brain. Mol. Ther.15 (9), 1593–1599 (2007).
   PubMed Web of Science ®Google Scholar
• Turowska A , LibrizziD, BaumgartlNet al. Biodistribution of the GATA-3-specific DNAzyme hgd40 after inhalative exposure in mice, rats and dogs. Toxicol. Appl. Pharmacol.272 (2), 365–372 (2013).
   PubMed Web of Science ®Google Scholar
• Konopka K , RossiJJ, SwiderskiP, SlepushkinVA, DuzgunesN. Delivery of an anti-HIV-1 ribozyme into HIV-infected cells via cationic liposomes. Biochim. Biophys. Acta1372 (1), 55–68 (1998).
   PubMed Web of Science ®Google Scholar
• Mackay SL , TannahillCL, AuffenbergT, KsontiniR, CopelandEM3rd, MoldawerLL. Characterization in vitro and in vivo of hammerhead ribozymes directed against murine tumor necrosis factoralpha. Biochem. Biophys. Res. Commun.260 (2), 390–397 (1999).
   PubMed Web of Science ®Google Scholar
• Abounader R , LalB, LuddyCet al. In vivo targeting of SF/HGF and c-met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis. FASEB J.16 (1), 108–110 (2002).
   PubMedGoogle Scholar
• Nosrati M , LiS, BagheriSet al. Antitumor activity of systemically delivered ribozymes targeting murine telomerase RNA. Clin. Cancer Res.10 (15), 4983–4990 (2004).
   PubMed Web of Science ®Google Scholar
• Duzgunes N , SimoesS, SlepushkinVet al. Enhanced inhibition of hiv-1 replication in macrophages by antisense oligonucleotides, ribozymes and acyclic nucleoside phosphonate analogs delivered in ph-sensitive liposomes. Nucleosides Nucleotides Nucl. Acids20 (4–7), 515–523 (2001).
   PubMed Web of Science ®Google Scholar
• Kitajima I , HanyuN, SoejimaYet al. Efficient transfer of synthetic ribozymes into cells using hemagglutinating virus of japan (HVJ)-cationic liposomes. Application for ribozymes that target human t-cell leukemia virus type i tax/rex mRNA. J. Biol. Chem.272 (43), 27099–27106 (1997).
   PubMed Web of Science ®Google Scholar
• Li Y , BhindiR, DengZJ, MortonSW, HammondPT, KhachigianLM. Inhibition of vein graft stenosis with a c-jun targeting dnazyme in a cationic liposomal formulation containing 1,2-dioleoyl-3-trimethylammonium propane (dotap)/1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (dope). Int. J. Cardiol.168 (4), 3659–3664 (2013).
   PubMed Web of Science ®Google Scholar
• Chan CW , KaplanW, ParishCR, KhachigianLM. Reduced retinal microvascular density, improved forepaw reach, comparative microarray and gene set enrichment analysis with c-jun targeting DNA enzyme. PLoS ONE7 (7), e39160 (2012).
   PubMed Web of Science ®Google Scholar
• Cho EA , MoloneyFJ, CaiHet al. Safety and tolerability of an intratumorally injected DNAzyme, DZ13, in patients with nodular basal-cell carcinoma: a Phase 1 first-in-human trial (discover). Lancet381 (9880), 1835–1843 (2013).
   PubMed Web of Science ®Google Scholar
• Barchet W , WimmenauerV, SchleeM, HartmannG. Accessing the therapeutic potential of immunostimulatory nucleic acids. Curr. Opin. Immunol.20 (4), 389–395 (2008).
   PubMed Web of Science ®Google Scholar
• Weiner GJ . The immunobiology and clinical potential of immunostimulatory cpg oligodeoxynucleotides. J. Leukoc. Biol.68 (4), 455–463 (2000).
   PubMed Web of Science ®Google Scholar
• Wilson KD , De JongSD, TamYK. Lipid-based delivery of CPG oligonucleotides enhances immunotherapeutic efficacy. Adv. Drug Deliv. Rev.61 (3), 233–242 (2009).
   PubMed Web of Science ®Google Scholar
• Mui B , RaneySG, SempleSC, HopeMJ. Immune stimulation by a CPG-containing oligodeoxynucleotide is enhanced when encapsulated and delivered in lipid particles. J. Pharmacol. Exp. Ther.298 (3), 1185–1192 (2001).
   PubMed Web of Science ®Google Scholar
• Gursel I , GurselM, IshiiKJ, KlinmanDM. Sterically stabilized cationic liposomes improve the uptake and immunostimulatory activity of CpG oligonucleotides. J. Immunol.167 (6), 3324–3328 (2001).
   PubMed Web of Science ®Google Scholar
• Li WM , DragowskaWH, BallyMB, Schutze-RedelmeierMP. Effective induction of CD8+ T-cell response using CpG oligodeoxynucleotides and HER-2/neu-derived peptide co-encapsulated in liposomes. Vaccine21 (23), 3319–3329 (2003).
   PubMed Web of Science ®Google Scholar
• Li WM , BallyMB, Schutze-RedelmeierMP. Enhanced immune response to T-independent antigen by using CpG oligodeoxynucleotides encapsulated in liposomes. Vaccine20 (1–2), 148–157 (2001).
   PubMed Web of Science ®Google Scholar
• De Jong S , ChikhG, SekirovLet al. Encapsulation in liposomal nanoparticles enhances the immunostimulatory, adjuvant and anti-tumor activity of subcutaneously administered CpG ODN. Cancer Immunol. Immunother.56 (8), 1251–1264 (2007).
   PubMed Web of Science ®Google Scholar
• Wilson KD , RaneySG, SekirovLet al. Effects of intravenous and subcutaneous administration on the pharmacokinetics, biodistribution, cellular uptake and immunostimulatory activity of CpG ODN encapsulated in liposomal nanoparticles. Int. Immunopharmacol.7 (8), 1064–1075 (2007).
   PubMed Web of Science ®Google Scholar
• Lin PJ , TamYK, CullisPR. Development and clinical applications of siRNA-encapsulated lipid nanoparticles in cancer. Clin. Lipidol.9, 317–331 (2014).
   Web of Science ®Google Scholar
• Anderson BR , MuramatsuH, NallagatlaSRet al. Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation. Nucleic Acids Res.38 (17), 5884–5892 (2010).
   PubMed Web of Science ®Google Scholar
• Kariko K , MuramatsuH, LudwigJ, WeissmanD. Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA. Nucleic Acids Res.39 (21), e142 (2011).
   PubMed Web of Science ®Google Scholar
• Anderson BR , MuramatsuH, JhaBK, SilvermanRH, WeissmanD, KarikoK. Nucleoside modifications in RNA limit activation of 2’-5’-oligoadenylate synthetase and increase resistance to cleavage by RNAse l. Nucleic Acids Res.39 (21), 9329–9338 (2011).
   PubMed Web of Science ®Google Scholar